Skip to content

Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes

The Impact of Exercise on Vascular Remodeling, Arteriovenous Fistula Creation and Use in Patients With Chronic Kidney Disease: A Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02205944
Enrollment
210
Registered
2014-08-01
Start date
2014-09-30
Completion date
2018-03-31
Last updated
2016-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease

Keywords

chronic kidney disease, hemodialysis, vascular access, arteriovenous fistula, forearm exercise

Brief summary

The purpose of this research study is to determine whether two different types of forearm exercise, performed before fistula creation surgery, can improve surgery success and fistula maturation.

Detailed description

This is a randomized, double blinded controlled trial to study the impact of handgrip exercise prior to surgical creation of hemodialysis fistula on vascular remodelling and fistula maturation in chronic kidney disease patients.

Interventions

OTHERProgressive Handgrip Exercise

Group 1 (Normal Exercise Group): Daily, at home for 20 minutes using an adjustable handgrip trainer up to 8 weeks prior to a scheduled surgery for fistula creation. The exercise intensity is tailored using the Borg CR100 scale (Borg & Borg, 2001). Group 2 (Restricted Blood Flow Exercise Group): Same as the exercise performed by Group 1 with controlled tourniquet.

Sponsors

University Health Network, Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adult (age\>18 years old) with chronic kidney disease 2. Hemodialysis is their renal replacement therapy (RRT) modality 3. Deemed eligible for an arteriovenous fistula 4. Anticipated RRT start \< 3 months (from the time of vascular surgery assessment) if predialysis 5. Scheduled surgical creation of fistula aniticpated \>= 8 weeks 6. Able to follow instructions for an exercise intervention 7. Able to provide informed written consent

Exclusion criteria

1. Life expectancy \< 6 months 2. Need for urgent vascular access (i.e. \<4 weeks) 3. Pre-existing fistula distal to site of newly scheduled fistula 4. Ipsilateral central stenosis or occlusions not amenable to correction 5. Contraindications or unable to perform handgrip exercise * Unable to withstand transiently raised systolic blood pressure (SBP) by 35 mmHg, and diastolic (DBP) by 25 mmHg * severe upper extremity arthritis or other pain 6. Contraindications to general exercise * Poorly controlled blood pressure - SBP\>180, DBP\>90; SBP\<110, DBP\<50 * NYHC IV heart failure

Design outcomes

Primary

MeasureTime frameDescription
Late dialysis suitability failure6 months after surgeryLate dialysis suitability failure is a fistula that, despite radiological or surgical intervention, cannot be used successfully for dialysis by the sixth month following its creation.

Secondary

MeasureTime frameDescription
Change of intra-access flow and vascular diameters at predetermined distances from the fistula anastomosis; arterial stiffness and endothelial function on a randomly determined sub sample of patients.Baseline, week 9 and week 11Ultrasound measurements using duplex ultrasonography
Plasma cGMP (cyclic guanosine monophosphate) and NO (nitric oxide) levelsBaseline, week 9 and week 11cGMP and NO will be sampled in blood plasma collected immediately prior to ultrasound assessment
Fistula maturation6 weeks after surgeryA fistula will be deemed mature if either criterion are met: 1) the National Kidney Foundation Disease Outcomes Quality Initiative 'rule of six' , or 2) the draining vein diameter is \> 4 mm with intra-access flows \> 500 ml/min AND an experienced hemodialysis nurse, blinded to group allocation, deems maturation to have occurred.

Countries

Canada

Contacts

Primary ContactCathy Forrester, RN
Cathy.Forrester@uhn.ca416-340-4748

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026